Marleen van den Horst

T: +31 70 376 06 21
E: marleen.vandenhorst@barentskrans.nl
View Marleen van den Horst on LinkedIn

Marleen van den Horst is partner in the IP and Technology practice group and heads the industry group Healthcare and Life Sciences. Marleen has ample experience in conducting complex, cross-border proceedings on intellectual property. Specialised in patent law, she handles cases involving mechanical engineering, electrical engineering, chemistry and life sciences. These deal with topics ranging from hatch covers, electronic braille cells, sports field maintenance machines and flower bulb sorting machines to medical equipment and medicinal products. Marleen has achieved international recognition in the field of life sciences. She handles patent and regulatory proceedings regarding medicinal products with active ingredients such as ciclosporin, omeprazole, escitalopram, trastuzumab, zoledronate, imatinib, rituximab, ezetimibe/simvastatin and CRISPR-Cas9 technology. Aside from litigation, Marleen also assists clients in negotiating and drawing up licences, technology transfers and distribution and cooperation agreements.

Selected directory listings

“She pushes forward energetically and is always ready to pursue unconventional approaches if they look promising.” – IAM Patent 1000, 2020

Practice head Marleen Van Den Horst has a well-established expertise in generic pharmaceuticals and is a ‘highly skilled litigator’ with ‘creative and commercially sound suggestions’Legal 500, 2020

Marleen Van den Horst is praised by clients for maintaining a “really good oversight” of cases. Her practice centres on contentious patent cases, where she frequently represents multinational pharmaceutical clients. – Chambers Global & Europe 2020

Marleen Van Den Horst heads the practice at BarentsKrans which has ‘respected lawyers with a broad network’ and who ‘go into depth in understanding technology and provide a strategy‘. Van den Horst has decades of experience in relation to litigation over blockbuster drugs and regulatory proceedings. – Legal 500, 2019

According to sources, Marleen van den Horst is ”a very good lawyer with excellent judicial skills.”Chambers Global 2019

Professional activities

Member of the Board of the NeoKidney Foundation
Member of various professional associations, including EPLAW, AIPPI, LES, HollandBio, VF&R and VIEPA.

She is a frequent speaker on international conferences.

News and publications

Pharma update | Dutch Court of Appeal: Pemetrexed patent Eli Lilly valid and infringed

In its judgment of 27 October 2020, the Court of Appeal of The Hague found that the generic pemetrexed tromethamine product of Fresenius Kabi Nederland B.V. (“Fresenius”) infringes EP 1 313 508 (‘EP‘508’), held by Eli Lilly and Company (“Lilly”). Yet again a turn of events in Dutch case law, where this issue has been
Read more ›

Pharma update | AstraZeneca ordered to compensate damage health insurer Menzis for enforcing invalid patent

In a groundbreaking judgment of 14 October 2020, the District Court of The Hague ruled that AstraZeneca AB (‘AstraZeneca’) must compensate health insurer Menzis Zorgverzekeraar NV (‘Menzis’) for having enforced a patent that was later invalidated. AstraZeneca owned European patent EP 0 907 364 (“EP 364”) for a sustained-release (XR) formulation of quetiapine, an active
Read more ›

Pharma update | Cross-border preliminary injunction granted regarding deferasirox

At the request of Novartis the Provisions Judge of the District Court of The Hague granted a preliminary injunction against Mylan BV for the alleged imminent infringement of Novartis’ paediatric extension (‘PE’) of Dutch SPC 300248 (‘SPC ‘248’) based on EP 0 914 118 (‘EP ‘118’).The product at issue contains deferasirox as the active ingredient
Read more ›

Pharma update | NPS’s cinacalcet patent held valid by Court of Appeal

EP ‘761, owned by Shire-NPS Pharmaceuticals Inc. (‘NPS’), relates to the API cinacalcet, which is used for the treatment of conditions of impaired regulation of calcium levels in human blood and tissue fluid. The product is marketed under the name Mimpara®. In September 2017, Accord Healthcare Ltd. and Accord Healthcare B.V. (‘Accord’) initiated invalidity proceedings
Read more ›
More from this specialist